The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.
Jean-Charles Soria
No relevant relationships to disclose
Filippo G. De Braud
Consultant or Advisory Role - EOS GmbH; Novartis; Roche; SERVIER
Research Funding - Novartis; SERVIER
Ratislav Bahleda
No relevant relationships to disclose
Barbara Adamo
No relevant relationships to disclose
Roberta Cereda
Employment or Leadership Position - EOS S.p.A.
Maria Gabriella Camboni
Employment or Leadership Position - EOS S.p.A.
Stock Ownership - Clovis
Renata Robert
Employment or Leadership Position - Iris
Jeffrey D. Isaacson
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Jason B. Litten
Employment or Leadership Position - Clovis
Stock Ownership - Amgen; Clovis
Andrew R. Allen
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Lindsey Rolfe
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Josep Tabernero
Consultant or Advisory Role - Amgen; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck KGaA; Millennium; Novartis; Roche; Sanofi ; Taiho Pharmaceutical
Honoraria - Amgen; Merck KGaA; Novartis; Roche; Sanofi